QQQ   269.85 (+0.17%)
GOOGL   1,478.00 (-0.32%)
QQQ   269.85 (+0.17%)
GOOGL   1,478.00 (-0.32%)
QQQ   269.85 (+0.17%)
GOOGL   1,478.00 (-0.32%)
QQQ   269.85 (+0.17%)
GOOGL   1,478.00 (-0.32%)
Log in

OTCMKTS:WINTWindtree Therapeutics Stock Price, Forecast & News

+1.53 (+18.28 %)
(As of 08/4/2020 09:30 AM ET)
Today's Range
Now: $9.90
50-Day Range
MA: $7.04
52-Week Range
Now: $9.90
Volume293,278 shs
Average Volume22,094 shs
Market Capitalization$135.60 million
P/E RatioN/A
Dividend YieldN/A
Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Read More
Windtree Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolOTCMKTS:WINT
Previous SymbolNASDAQ:WINT



Sales & Book Value

Annual Sales$200,000.00
Book Value$5.12 per share


Net Income$-27,480,000.00


Market Cap$135.60 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
+1.53 (+18.28 %)
(As of 08/4/2020 09:30 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions

How has Windtree Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Windtree Therapeutics' stock was trading at $3.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, WINT stock has increased by 167.6% and is now trading at $9.90.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Windtree Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Windtree Therapeutics

When is Windtree Therapeutics' next earnings date?

Windtree Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Windtree Therapeutics

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics Inc (OTCMKTS:WINT) posted its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.48) earnings per share for the quarter.
View Windtree Therapeutics' earnings history

When did Windtree Therapeutics' stock split? How did Windtree Therapeutics' stock split work?

Windtree Therapeutics shares reverse split on Wednesday, April 29th 2020. The 1-3 reverse split was announced on Tuesday, April 28th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 28th 2020. An investor that had 100 shares of Windtree Therapeutics stock prior to the reverse split would have 33 shares after the split.

What price target have analysts set for WINT?

1 brokerages have issued 12-month target prices for Windtree Therapeutics' stock. Their forecasts range from $12.25 to $12.25. On average, they anticipate Windtree Therapeutics' share price to reach $12.25 in the next twelve months. This suggests a possible upside of 23.7% from the stock's current price.
View analysts' price targets for Windtree Therapeutics

Has Windtree Therapeutics been receiving favorable news coverage?

Media stories about WINT stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Windtree Therapeutics earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Windtree Therapeutics

Who are some of Windtree Therapeutics' key competitors?

What other stocks do shareholders of Windtree Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Windtree Therapeutics investors own include La Jolla Pharmaceutical (LJPC), Trevena (TRVN), NovaBay Pharmaceuticals (NBY), XOMA (XOMA), CTI BioPharma (CTIC), Reshape Lifesciences (RSLS), CorMedix (CRMD), Microbot Medical (MBOT), Novavax (NVAX) and SLS International (SLS).

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the following people:
  • Mr. Craig E. Fraser, Pres, CEO & Director (Age 54)
  • Mr. John A. Tattory, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 60)
  • Mr. George Cox, VP of Manufacturing & Supply Chain and Technical Operations (Age 67)
  • Ms. Mary B. Templeton, Sr. VP, Gen. Counsel & Corp. Sec. (Age 72)

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."

Who are Windtree Therapeutics' major shareholders?

Windtree Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include UBS Group AG (0.03%). Company insiders that own Windtree Therapeutics stock include James Huang and Lph Ii Investments Ltd.
View institutional ownership trends for Windtree Therapeutics

Which institutional investors are buying Windtree Therapeutics stock?

WINT stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Windtree Therapeutics stock in the last two years include James Huang, and Lph Ii Investments Ltd.
View insider buying and selling activity for Windtree Therapeutics

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $9.90.

How big of a company is Windtree Therapeutics?

Windtree Therapeutics has a market capitalization of $135.60 million and generates $200,000.00 in revenue each year. Windtree Therapeutics employs 27 workers across the globe.

What is Windtree Therapeutics' official website?

The official website for Windtree Therapeutics is www.windtreetx.com.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.